Ramucirumab (Cyramza)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Colorectal cancer

Gastric cancer

Hepatocellular carcinoma

Non-small cell lung cancer

History of changes in EMA indication

  • 2014-12-16: Initial marketing authorization as Cyramza.

History of changes in Health Canada indication

  • 2015-07-16: Initial notice of compliance as a single agent for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.
  • 2015-07-16: Initial notice of compliance in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression on or after prior platinum and fluoropyrimidine chemotherapy.

History of changes in PMDA indication

  • 2015-03-26: Initial approval for the treatment of unresectable advanced or recurrent gastric cancer.
  • 2016-05-23: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent colorectal cancer.
  • 2016-06-20: New additional indication and a new dosage for the treatment of unresectable advanced/relapsed non-small cell lung cancer.
  • 2019-06-18: New indication for the treatment of patients with unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy.

Also known as

  • Code names: IMC-1121B, LY-3009806
  • Brand name: Cyramza

References